Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma

Pembrolizumab regimen extends PFS in advanced, recurrent endometrial carcinoma

The addition of pembrolizumab to chemotherapy significantly extended PFS as first-line treatment for advanced or recurrent endometrial carcinoma, according to the agent’s manufacturer. Pembrolizumab (Keytruda, Merck), an anti-PD-1 therapy, also exhibited a safety profile consistent with prior studies, with no new safety signals.

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma

KEYTRUDA plus chemotherapy significantly improved PFS versus standard of care chemotherapy alone as first-line treatment for patients with stage III-IV or recurrent endometrial carcinoma regardless of mismatch repair status Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 NRG-GY018 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with standard of care chemotherapy (carbo

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma

Real-Time News, Market Data, and Stock Quotes for Healthcare Stocks @ healthstockshub.com

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma

Merck’s KEYTRUDA Plus Chemotherapy Met Primary Endpoint of PFS as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma